At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21,283 enrolled
Drug / intervention
No intervention given in this observational study +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Dec 15, 2010·Updated Feb 1, 2021
In Brief
An observational study evaluating No intervention given in this observational study for Anterior Ischemic Optic Neuropathy and Ischemic Optic Neuropathy. Completed, enrolled 21,283 participants.
Detailed Summary
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
Primary CompletionMar 2010
First PostedDec 2010
TodayJul 2026
First PostedDec 15, 2010
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.5 years ago
Interventions
No intervention given in this observational studyother
No intervention given in this observational study
No intervention given in this observational studyother
No intervention given in this observational study